396 related articles for article (PubMed ID: 29557200)
1. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.
Carrascosa JM; Del-Alcazar E
Expert Rev Clin Immunol; 2018 Apr; 14(4):259-273. PubMed ID: 29557200
[TBL] [Abstract][Full Text] [Related]
2. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ; Warren RB; Cather JC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
[TBL] [Abstract][Full Text] [Related]
3. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
[No Abstract] [Full Text] [Related]
4. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis.
Green LJ; Yamauchi PS; Kircik LH
J Drugs Dermatol; 2019 Aug; 18(8):776-788. PubMed ID: 31424708
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.
Carrascosa JM; van Doorn MB; Lahfa M; Nestle FO; Jullien D; Prinz JC
J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1424-30. PubMed ID: 24841895
[TBL] [Abstract][Full Text] [Related]
7. Severe and acute complications of biologics in psoriasis.
Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis reactivation risk in dermatology.
Pescitelli L; Ricceri F; Prignano F
J Rheumatol Suppl; 2014 May; 91():65-70. PubMed ID: 24789002
[TBL] [Abstract][Full Text] [Related]
9. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG
Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926
[TBL] [Abstract][Full Text] [Related]
10. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
Kolli SS; Kepley AL; Cline A; Feldman SR
Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects of biologic drugs in psoriasis: a literature review.
Šuler Baglama Š; Trčko K
Acta Dermatovenerol Alp Pannonica Adriat; 2021 Dec; 30(4):149-156. PubMed ID: 34929991
[TBL] [Abstract][Full Text] [Related]
12. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
Campanati A; Molinelli E; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
14. [Biologics. New drugs, new adverse reactions].
Prinz JC
Hautarzt; 2010 Aug; 61(8):668-75. PubMed ID: 20585746
[TBL] [Abstract][Full Text] [Related]
15. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
Yamauchi PS; Bagel J
J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
[TBL] [Abstract][Full Text] [Related]
16. Durability and long-term outcomes of biologic therapies in psoriasis.
Rusiñol L; Carmona-Rocha E; Puig L
Expert Rev Clin Immunol; 2024; 20(1):71-82. PubMed ID: 37610817
[TBL] [Abstract][Full Text] [Related]
17. Switching biologics in psoriasis - practical guidance and evidence to support.
Tsai YC; Tsai TF
Expert Rev Clin Pharmacol; 2020 May; 13(5):493-503. PubMed ID: 32394765
[TBL] [Abstract][Full Text] [Related]
18. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
19. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
20. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]